PUBLICATIONS
- Computing exact p-values for a cross-correlation
shotgun proteomics scoring function. JJ Howbert and WS
Noble. (submitted).
- Fast exact counting of graph cycles C6 to C9 using
powers of the adjacency matrix. JJ Howbert.
(submitted).
- Forecasting seizures in dogs with naturally occurring
epilepsy. JJ Howbert, EE Patterson, SM Stead, V Vasoli,
D Crepeau, CH Vite, B Sturges, V Ruedebusch, J Mavoori,
K Leyde, WD Sheffield, B Litt, and GA Worrell. PLOS ONE
(accepted).
- Identifying the structural architecture of the human
inferior parietal lobule using diffusion MRI. RF
Tungaraza, JJ Howbert, SH Mehta, DR Haynor, LG Shapiro,
and TJ Grabowski. IEEE International Symposium on
Biomedical Imaging, Barcelona, Spain, 2012, pp. 506-50.
- VTX-2337 is a novel TLR8 agonist that activates NK
cells and augments ADCC. H Lu, GN Dietsch, MH
Matthews, Y Yang, S Ghanekar, M Inokuma, M Suni, VC
Maino, KE Henderson, JJ Howbert, ML Disis, and RM
Hershberg. Clin. Cancer Res. 18: 499, 2012.
- MR-Tandem: Parallel X!Tandem using Hadoop MapReduce on
Amazon Web Services. B Pratt, JJ Howbert, NI
Tasman, and EJ Nilsson. Bioinformatics 28: 136,
2012.
- Identification of TNF-alpha inhibitors from a
split-pool library based on a tyrosine-proline
peptidomimetic scaffold. RW Jackson, JC Tabone,
and JJ Howbert. Bioorg. Med. Chem. Lett. 13: 205,
2003.
- Benzobicyclooctanes as novel inhibitors of TNF-alpha
signaling. RW Jackson, R Gelinas, TA Baughman, T
Cox, JJ Howbert, KA Kucera, JA Latham, F Ramsdell, D
Singh, and IS Darwish. Bioorg. Med. Chem. Lett.
12: 1093, 2002.
- Insights from model systems. Of monkeys and men:
vervets and the genetics of human-like behaviors.
RM Palmour, J Mulligan, JJ Howbert, and F Ervin.
Am. J. Hum. Genet. 61: 481, 1997.
- [3H]LY303870, a novel nonpeptide radioligand for the
NK-1 receptor. DR Gehlert, DA Schober, PA
Hipskind, BD Gitter, and JJ Howbert. J. Neurochem.
66: 1095, 1996.
- 3-Aryl-1,2-diacetamidopropane derivatives as novel and
potent NK-1 receptor antagonists. PA Hipskind, JJ
Howbert, RF Bruns, SSY Cho, TA Crowell, MM Foreman, DR
Gehlert, S Iyengar, KW Johnson, JH Krushinski, DL Li, KL
Lobb, NR Mason, BS Muehl, JA Nixon, LA Phebus, D Regoli,
RM Simmons, PG Threlkeld, DC Waters, and BD
Gitter. J. Med. Chem. 39: 736, 1996.
- Pharmacological characterization of LY303870: a novel,
potent, and selective non-peptide substance P
(neurokinin-1) receptor antagonist. BD Gitter, RF
Bruns, JJ Howbert, DC Waters, PG Threlkeld, LM Cox, JA
Nixon, KL Lobb, NR Mason, PW Stengel, SL Cockerham, SA
Silbaugh, DR Gehlert, DA Schober, S Iyengar, DO
Calligaro, D Regoli, and PA Hipskind. J. Pharm.
Exp. Therap. 275: 737, 1995.
- Practical and enantiospecific synthesis of LY303870, a
novel NK-1 antagonist. PA Hipskind, JJ Howbert, S
Cho, JS Cronin, SL Fort, FO Ginah, GJ Hansen, BE Huff,
KL Lobb, MJ Martinelli, AR Murray, JA Nixon, MA Staszak,
and JD Copp. J. Org. Chem. 60: 7033, 1995.
- The discovery of a novel class of potent, non-peptide
substance P (NK-1) receptor antagonists. PA
Hipskind, JJ Howbert, L Phebus, R Bruns, SS Cho, TA
Crowell. Pharmacol. Toxicol. 76: S14, 1995.
- (R)-Thionisoxetine, a potent and selective inhibitor
of central and peripheral norepinephrine uptake.
DR Gehlert, SK Hemrick-Luecke, DA Schober, J Krushinski,
JJ Howbert, DW Robertson, DT Wong, and RW Fuller.
Life Sciences 56: 1915, 1995.
- Novel halogenated analogs of tomoxetine that are
potent and selective inhibitors of norepinephrine uptake
in brain. DR Gehlert, DA Schober, SK
Hemrick-Luecke, J Krushinski, JJ Howbert, DW Robertson,
RW Fuller, and DT Wong. Neurochem. Internat. 26:
47, 1995.
- Interleukin-6 secretion from human astrocytoma cells
induced by substance P. BD Gitter, D Regoli, JJ
Howbert, AL Glasebrook, and DC Waters. J.
Neuroimmunol. 51: 101, 1994.
- Inhibition of A9 and A10 dopamine cells by the
cholecystokinin-B antagonist LY262691: mediation through
feedback pathways from forebrain sites. K
Rasmussen, JJ Howbert, and ME Stockton. Synapse,
15: 95, 1993.
- Use of non-peptide tachykinin receptor antagonists to
substantiate the involvement of NK1 and NK2 receptors in
a spinal nociceptive reflex in the rat. P Picard,
S Boucher, D Regoli, BD Gitter, JJ Howbert, and R
Couture. Eur. J. Pharmacol. 232: 255, 1993.
- Tachykinin receptor antagonists inhibit
hyperpnea-induced bronchoconstriction in guinea
pigs. J Solway, BM Kao, JE Jordan, B Gitter, IW
Rodger, JJ Howbert, LE Alger, J Necheles, AR Leff, and A
Garland. J. Clin. Invest. 92: 315, 1993.
- Pharmacokinetics of the anticancer agent sulofenur in
mice, rats, monkeys and dogs. WJ Ehlhardt, HR
Sullivan, PG Wood, JM Woodland, M Hamilton, C Hamilton,
D Cornprobst, GB Grindey, JF Worzalla, JR Bewley, GC
Todd, and JJ Howbert. J. Pharmaceut. Sci. 82: 683,
1993.
- Diphenylpyrazolidinone and benzodiazepine
cholecystokinin antagonists: a case of convergent
evolution in medicinal chemistry. JJ Howbert, KL
Lobb, TC Britton, NR Mason, and RF Bruns. Bioorg.
Med. Chem. Lett. 3: 875, 1993.
- Electrophysiological effects of diphenylpyrazolidinone
cholecystokinin-B and cholecystokinin-A antagonists on
midbrain dopamine neurons. K Rasmussen, JF
Czachura, ME Stockton, and JJ Howbert. J. Pharm.
Exp. Therap. 264: 480, 1993.
- Comparison of metabolism and toxicity to the structure
of the anticancer agent sulofenur and related
sulfonylureas. WJ Ehlhardt, JM Woodland, JF
Worzalla, JR Bewley, GB Grindey, GC Todd, JE Toth, and
JJ Howbert. Chem. Res. Toxicol. 5: 667, 1992.
- A novel series of non-peptide CCK and gastrin
antagonists: medicinal chemistry and
electrophysiological demonstration of antagonism.
JJ Howbert, KL Lobb, RF Brown, JK Reel, DA Neel, NR
Mason, LG Mendelsohn, JP Hodgkiss, and JS Kelly.
In Multiple Cholecystokinin Receptors in the CNS; CT
Dourish, SJ Cooper, SD Iversen, and LL Iversen, Eds.;
Oxford University Press: London, 1992, 28-37.
- Inhibition of PAIII rat prostatic adenocarcinoma
growth and metastasis by a new diarylsulfonylurea
antitumor agent, LY181984. BL Neubauer, RL
Merriman, KL Best, RL Goode, MF Sarosdy, LR Tanzer, and
JJ Howbert. J. Urology 147: 500, 1992.
- Cholecystokinin (CCK) and schizophrenia: the selective
CCK-B antagonist LY262691 decreases midbrain dopamine
unit activity. K Rasmussen, ME Stockton, JF
Czachura, and JJ Howbert. Eur. J. Pharmacol. 209:
135, 1991.
- Sulofenur. JJ Howbert. Monograph in: Drugs
Future 16: 517, 1991.
- Species differences in affinities of nonpeptide
antagonists for substance P receptors. BD Gitter,
DC Waters, RF Bruns, NR Mason, JA Nixon, and JJ
Howbert. Eur. J. Pharmacol. 197: 237, 1991.
- Selectivity and specificity of new, non-peptide,
quinuclidine antagonists of substance P. N
Rouissi, BD Gitter, DC Waters, JJ Howbert, JA Nixon, and
D Regoli. Biochem. Biophys. Res. Comm. 176: 894,
1991.
- Inhibition of protein kinase C by calphostin C is
light-dependent. RF Bruns, FD Miller, RL Merriman,
JJ Howbert, WF Heath, E Kobayashi, I Takahashi, T
Tamaoki, and H Nakano. Biochem. Biophys. Res.
Comm. 176: 288, 1991.
- Metabolism and disposition of p-chloroaniline in rat,
mouse, and monkey. WJ Ehlhardt and JJ
Howbert. Drug Metab. Dispos. 19: 366, 1991.
- Synthesis of N-(1-keto-) and
N-(1-hydroxy-5-indansulfonyl)-N'-(4-chlorophenyl)urea,
two major metabolites of the antitumor agent sulofenur
(LY186641). JJ Howbert and TA Crowell.
Synthetic Comm. 20: 3193, 1990.
- Novel agents effective against solid tumors: the
diarylsulfonylureas. Synthesis, activities, and analysis
of quantitative structure-activity relationships.
JJ Howbert, CS Grossman, TA Crowell, BJ Rieder, RW
Harper, KE Kramer, EV Tao, J Aikens, GA Poore, SM
Rinzel, GB Grindey, WN Shaw, and GC Todd. J. Med.
Chem. 33: 2393, 1990.
- Evidence for mitochondrial localization of
N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in
human colon adenocarcinoma cells. PJ Houghton, FC
Bailey, JA Houghton, KG Murti, JJ Howbert, and GB
Grindey. Cancer Res. 50: 664, 1990.
- Studies on the cellular pharmacology of
N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea.
PJ Houghton, FC Bailey, GS Germain, GB Grindey, JJ
Howbert, and JA Houghton. Biochem. Pharmacol. 39:
1187, 1990.
- Evaluation of
N-5-(indanylsulfonyl)-N'-(4-chlorophenyl)urea against
xenografts of pediatric rhabdomyosarcoma. PJ
Houghton, JA Houghton, L Myers, PJ Cheshire, JJ Howbert,
and GB Grindey. Cancer Chemother. Pharmacol. 26:
84, 1989.
- Potent inhibition of interleukin 1b-mediated human
melanoma (A375.6) lysis by corticosteroids,
staurosporine, and tilorone. RM Schultz, JJ
Howbert, and RA Archer. Immunopharmacol.
Immunotoxicol. 11: 489, 1989.
- Synthetic studies on areneolefin cycloadditions -VI-
two syntheses of (+-)-coriolin. PA Wender and JJ
Howbert. Tetrahedron Lett. 5325, 1983.
- Synthetic studies on areneolefin cycloadditions -III-
total synthesis of (+-)-hirsutene. PA Wender and
JJ Howbert. Tetrahedron Lett. 3983, 1982.
- Synthetic studies on areneolefin cycloadditions: total
synthesis of (+-)-cedrene. PA Wender and JJ
Howbert. J. Am. Chem. Soc. 103: 688, 1981.
- Derivatives of trifluorovinylsulfur pentafluoride
(SF5CF=CF2) - II. R DeBuhr, J Howbert, JM Canich,
HF White, and GL Gard. J. Fluorine Chem. 20: 515,
1982.
POSTERS AND ABSTRACTS
- Continuous intracranial EEG recording and seizure
forecasting in dogs with naturally occurring epilepsy.
EE Patterson, JJ Howbert, SM Stead, V Vasoli, D Crepeau,
CH Vite, B Sturges, V Ruedebusch, LD Coles, J Mavoori, K
Leyde, WD Sheffield, B Litt, and GA Worrell. 3rd
International Conference on Medical Bionics, Philip
Island, Victoria, Australia, Nov. 17-20, 2013.
- Progress on development of neurophysiologically-based
responsive therapy in dogs with naturally occurring
epilepsy. G Worrell, E Patterson , C Vite, M Bower, V
Vasoli, B Sturges, V Ruedebusch, L Coles, J Cloyd, B
Brinkmann, M Stead, D Crepeau, J McDonnell, J Mavoori, J
Howbert, K Leyde, D Sheffield, and B Litt. American
Epilepsy Society, San Diego, CA, Nov. 30-Dec. 4, 2012.
- MR-Tandem: Parallel X!Tandem Using Hadoop MapReduce on
Amazon Web Services. BS Pratt, JJ Howbert, NI
Tasman, and EJ Nilsson. 2011 Cascadia Proteomics
Symposium, Seattle, WA, July 17-19, 2011.
- Synthesis of cleavable mass spectrometry tags: a
system for SNP genotyping. J Mathis, B Erwin, D
Galas, L Garrison, E Keeler, J Howbert, M Kokoris, C
Lock, K Moynihan, J Van Ness, B Skead, and J
Tabone. 3rd Lake Tahoe Symposium on Molecular
Diversity, Lake Tahoe, CA, Jan. 24-29, 1999.
- Synthesis of cleavable mass spectrometry tags: a
system for SNP genotyping. J Mathis, B Erwin, D
Galas, L Garrison, E Keeler, J Howbert, M Kokoris, C
Lock, K Moynihan, J Van Ness, B Skead, and J
Tabone. 3rd Winter Conference on Medicinal and
Bioorganic Chemistry, Steamboat Springs, CO, Jan. 23-29,
1999.
- Characterization of guinea pig NK1 receptors using the
potent antagonist ligand, [3H]LY303870 DR Gehlert,
DA Schober, PA Hipskind, J Nixon, BD Gitter, and JJ
Howbert. Soc. Neurosci. Abstr. 21: , 1995.
- Pharmacological characterization of LY303870: a novel,
potent, and selective non-peptide substance P receptor
antagonist. BD Gitter, RF Bruns, JJ Howbert, PW
Stengel, DR Gehlert, S Iyengar. Soc. Neurosci.
Abstr. 21: , 1995.
- Part I. Antitubercular agents from higher
plants: synthesis and in vivo activity of
indigo[2,1b]-quinazoline-6,12-diones and related
analogs. WR Baker, LA Mitscher, B Feng, S Cai, M
Clark, T Leung, JA Towell, I Darwish, J Howbert, K
Stover, A Resconi, TM Arain, et al. 35th
Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), San Francisco, CA, Abstract F16,
Sept. 1995.
- The discovery of LY303870, a novel and potent
non-peptide substance P (NK-1) receptor antagonist with
a long duration of action. PA Hipskind, RF Bruns,
DR Gehlert, JJ Howbert, S Iyengar, LA Phebus. AFMC
International Medicinal Chemistry Symposium/AIMECS 95,
Tokyo, Japan, Sept. 3-8, 1995.
- The discovery of a novel class of potent, non-peptide
substance P (NK-1) antagonists. PA Hipskind, JJ
Howbert, L Phebus, R Bruns, SS Cho, TA Crowell, KW
Johnson, KL Lobb, JH Krushinski, NR Mason, BS Muehl, JA
Nixon, PG Threlkeld, DC Waters, and BD Gitter. 5th
Annual European Neuropeptide Meeting, Lund, Sweden, June
3-7, 1995.
- Biochemical evaluation and autoradiographic
localization of the binding sites for the potent NK1
antagonist, [3H]LY303870. DR Gehlert, DA Schober,
JJ Howbert, J Nixon, BD Gitter, and PA Hipskind.
5th Annual European Neuropeptide Meeting, Lund, Sweden,
June 3-7, 1995.
- Virtual screening as a tool for evaluating chemical
libraries. RF Bruns, RMA Simmons, JJ Howbert, DC
Waters, PG Threlkeld, BD Gitter. Exploiting
Molecular Diversity: Small Molecule Libraries for Drug
Discovery, La Jolla, CA, Jan. 23-25, 1995.
- Structure-activity relationships of the novel
pyrazolidinone CCK antagonist LY262691. Effects of
substitution and replacement of the 4- and 5-phenyl
groups. JJ Howbert, KL Lobb, RF Brown, DA Neel, JK
Reel, NR Mason, and LG Mendelsohn. American
Chemical Society, Chicago, IL, Aug. 22-27, 1993.
- CCK and schizophrenia: CCK-B antagonists inhibit
dopamine neurons. K Rasmussen, JF Czachura, ME
Stockton, and JJ Howbert. 9th World Congress of
Psychiatry, Rio de Janiero, Brazil, June 6-12, 1993.
- Anxiogenic effects of CCK agonists in a non-human
primate model: central or peripheral? RM Palmour,
C Durieux, BP Roques, P Bertrand, M Capet, M-C
Dubroeucq, JJ Howbert, G Woodruff, J Bradwejn, and FR
Ervin. CCK '93: International Symposium, Chatham,
MA, May 19-22, 1993.
- Differential ability of a pyrazolidinone type A CCK
receptor antagonist (LY219057) to block the gastric
inhibitory and pyloric contractile actions of CCK.
JJ Howbert, GJ Schwartz, CF Salorio, KA Moore, and TH
Moran. CCK '93: International Symposium, Chatham,
MA, May 19-22, 1993.
- CCK, schizophrenia, and anxiety: electrophysiological
effects of CCK-B and CCK-A antagonists on midbrain
dopamine neurons. K Rasmussen, JF Czachura, ME
Stockton, and JJ Howbert. CCK '93: International
Symposium, Chatham, MA, May 19-22, 1993.
- CCK-B receptors tonically modulate A10 dopaminergic
neurons: neurochemical evaluation of LY288513. S
Iyengar, D Li, RM Simmons, JJ Howbert, and K
Rasmussen. CCK '93: International Symposium,
Chatham, MA, May 19-22, 1993.
- CCK-8 contracts the gallbladder and colon through
different mechanisms in the ferret. S Mitan, J
Howbert, and B Greenwood. CCK '93: International
Symposium, Chatham, MA, May 19-22, 1993.
- NK-1 receptor mediated anion transport in normal and
inflamed guinea pig colon. WE Albee, JJ Howbert,
and JS Gidda. American Gastroenterological
Association, Boston, MA, May 16-19, 1993.
- Mechanisms by which CCK-8 stimulates gallbladder and
colonic motility in the ferret. S Mitan, P Prime,
J Howbert, and B Greenwood. American
Gastroenterological Association, Boston, MA, May 16-19,
1993.
- Immunogenic inflammation augments tachykinin
responsiveness of guinea pig trachealis: mediation
through a neuronal release cascade? RW Mitchell,
IM Ndukwu, K Uzendowski, BD Gitter, JJ Howbert, J
Solway, and AR Leff. American Thoracic Society,
May, 1993.
- LY288513, an antagonist of brain cholecystokinin
(CCK-B) receptors, is active in preclinical models of
anxiety, panic disorder, and schizophrenia. JJ
Howbert, RF Bruns, LG Mendelsohn, RM Palmour, JE
Barrett, and K Rasmussen. American College of
Neuropsychopharmacology, San Juan, Puerto Rico, Dec.
14-18, 1992.
- Interleukin-6 secretion from the human astrocytoma
cell line, U-373 MG, induced by substance P. BD
Gitter, DC Waters, D Regoli, AL Glasebrook, and JJ
Howbert. International Symposium on Substance P
and Related Peptides, Shizuoka, Japan, Nov. 3-6, 1992.
- Histamine induces interleukin 6 release from the human
astrocytoma cell line, U-373 MG. DC Waters, RF
Bruns, JJ Howbert, and BD Gitter. Soc. Neurosci.
Abstr. 18:482, 1992.
- Localization of receptors mediating effects of the
selective CCK-B antagonist LY262691 on A9 and A10
dopamine cells: lesion and microinjection studies.
ME Stockton, JJ Howbert, and K Rasmussen. Soc.
Neurosci. Abstr. 18:278, 1992.
- Electrophysiological effects of diphenylpyrazolidinone
CCK-B and CCK-A antagonists on A9 and A10 dopamine
cells. JF Czachura, JJ Howbert, and K
Rasmussen. Soc. Neurosci. Abstr. 18:278, 1992.
- The NK-1 receptor antagonist (+)-CP-96,345 produces
biphasic changes in rat striatal dopamine release when
administered via a microdialysis probe. LA Phebus,
JJ Howbert, and JA Nixon. Soc. Neurosci. Abstr.
18:271, 1992.
- Inhibitory effects of an NK-1 (substance P) receptor
antagonist, (+)-CP-96,345, on visceral nociceptive
activity and non-nociceptive bladder activity in
rats. S Iyengar, MA Muhlhauser, JJ Howbert, and KB
Thor. Soc. Neurosci. Abstr. 18:271, 1992.
- Neurokinin-1 (NK-1) receptor blockade with (+/-)
CP-96,345 inhibits hyperpnea-induced bronchoconstriction
(HIB) in guinea pigs. A Garland, JE Jordan, R Kao,
B Gitter, J Howbert, J Necheles, and J Solway.
American Thoracic Society, Miami, FL, May 17-22, 1992.
- Inhibitory effects of an NK-1 (substance P) receptor
antagonist, (+)-CP-96,345, on bladder activity and
acetic acid-induced vesicoanal activity in rats.
KB Thor, MA Muhlhauser, JJ Howbert, and S Iyengar.
Society for Basic Urologic Research, Washington, D.C.,
May 8-9, 1992.
- The evaluation of candidate second generation
diarylsulfonylurea oncolytics. JE Toth, GB
Grindey, WJ Ehlhardt, GB Boder, JL Zimmerman, JP
McGrath, JJ Howbert, JR Bewley, KK Clingerman, SB Gates,
CS Grossman, JE Ray, SM Rinzel, RM Schultz, LC Weir, JM
Woodland, and JF Worzalla. 7th NCI-EORTC Symposium
on New Drugs in Cancer Therapy, Amsterdam, Netherlands,
Mar. 17-20, 1992.
- Anxiogenic and cardiovascular effects of CCK-4 in
monkeys are blocked by the CCK-B antagonist
LY262691. RM Palmour, FR Ervin, J Bradwejn, and JJ
Howbert. Soc. Neurosci. Abstr. 17:1602, 1991.
- Anxiolytic-like effects of the CCK-B antagonists
LY262691, LY262684, and LY247348 on punished responding
of squirrel monkeys. JE Barrett, MC Linden, MJ Yu,
and JJ Howbert. Soc. Neurosci. Abstr. 17:1063,
1991.
- Species differences in brain neuropeptide receptor
binding. NR Mason, RF Bruns, JJ Howbert, and MJ
Yu. Soc. Neurosci. Abstr. 17:808, 1991.
- Potent antagonism of the feeding inhibitory actions of
exogenous CCK-8 by a selective pyrazolidinone type A CCK
receptor antagonist (LY219057). JJ Howbert, NR
Mason, RF Bruns, LA Netterville, GJ Schwartz, and TH
Moran. Soc. Neurosci. Abstr. 17:491, 1991.
- Pharmacological characterization of new neurokinin
(substance P) antagonists. N Rouissi, BD Gitter,
JJ Howbert, D Jukic, and D Regoli. American
Society for Pharmacology and Experimental Therapeutics,
San Diego, CA, Aug. 16-20, 1991.
- New non-peptide pyrazolidinone cholecystokinin (CCK)
and gastrin antagonists. JJ Howbert. Joint
Great Lakes-Central Regional Meeting of American
Chemical Society, Indianapolis, IN, May 29-31, 1991.
- Evaluation of the mechanism of action of the
diarylsulfonylurea, LY181984, using 2-D gel
electrophoresis. RL Merriman, GB Grindey, JJ
Howbert, B Skidmore, and L Tanzer. Proc. Am.
Assoc. Cancer Res. 32:393, 1991.
- LY181984, a new diarylsulfonylurea with selective
antitumor activity against Ha-ras, but not Ki-ras,
transformed epithelial cells. RL Merriman, GB
Grindey, JJ Howbert, G Poore, K Shackelford, RA Swift,
and LR Tanzer. Proc. Am. Assoc. Cancer Res.
32:405, 1991.
- Evidence that gastrin receptors on AR4-2J cells are
distinct from CCK-B receptors, using novel
pyrazolidinone CCK antagonists. JJ Howbert, KL
Lobb, RF Brown, JK Reel, LG Mendelsohn, NR Mason, DF
Mahoney, and RF Bruns. Soc. Neurosci. Abstr.
16:82, 1990.
- LY262684, a novel pyrazolidinone CCK antagonist:
studies of contraction in guinea pig ileum. VL
Lucaites, LG Mendelsohn, NR Mason, ML Cohen, KL Lobb, RF
Brown, JK Reel, and JJ Howbert. Soc. Neurosci.
Abstr. 16:82, 1990.
- Antagonism of CCK-8 evoked excitation in the ventral
medial nucleus of the mouse by a new non-peptide CCK-B
antagonist, LY262691. JP Hodgkiss, JS Kelly, and
JJ Howbert. Multiple Cholecystokinin Receptors -
Progress Toward CNS Therapeutic Targets, Harlow,
England, Sept. 20-22, 1990.
- Medicinal chemistry of a novel series of non-peptide,
pyrazolidinone CCK and gastrin antagonists. JJ
Howbert, KL Lobb, RF Brown, JK Reel, DA Neel, NR Mason,
and LG Mendelsohn. Multiple Cholecystokinin
Receptors - Progress Toward CNS Therapeutic Targets,
Harlow, England, Sept. 20-22, 1990.
- 1-O-Alkylglycerols as inhibitors of phospholipase
A2. JJ Howbert, KL Lobb, CS Grossman, RL Merriman,
LR Tanzer, KA Shackelford, PP Ho, and B Bertsch.
American Chemical Society, Boston, MA, Apr. 22-27, 1990.
- Protein kinase C from rat brain: characterization and
inhibitor studies. LG Mendelsohn, VL Lucaites, and
JJ Howbert. Society for Neuroscience, Toronto,
Canada, Nov. 13-18, 1988.
- Molecular modeling of low energy conformations of
Ac-trp-met-asp-phe-NH2 [Ac-CCK-4] via exhaustive
conformational search, using Ac-(ala)4-NH2 as a
generalized tetrapeptide template. JJ
Howbert. CCK '88 - Symposium on Cholecystokinin,
Cambridge, England, Aug. 31-Sept. 2, 1988.
- Modeling of the indolocarbazole class of kinase
inhibitors - structural relationship to the common
phosphate donor, adenosine triphosphate. JJ
Howbert. Eli Lilly Modeling Conference,
Indianapolis, IN, Oct. 1-2, 1987.
- Effects of various compounds on interleukin 1-mediated
A375.6 human melanoma toxicity. RM Schultz, RA
Archer, JJ Howbert, and MG Altom. Proc. Am. Assoc.
Cancer Res. 28: 403, 1987.
- Further development of diarylsulfonylureas as novel
anticancer drugs. GB Grindey, GB Boder, CS
Grossman, JJ Howbert, GA Poore, WN Shaw, GC Todd, and JF
Worzalla. Proc. Am. Assoc. Cancer Res. 28: 309,
1987.
- Inhibition of PAIII rodent prostatic adenocarcinoma
growth and metastasis by a new sulfonylurea antitumor
agent, LY181984. BL Neubauer, KL Best, RL Goode,
RL Merriman, MF Sarosdy, LR Tanzer, and JJ
Howbert. J. Urology 135: 42, 1986.
- Identification of diarylsulfonylureas as novel
antitumor agents. GB Grindey, GB Boder, RW Harper,
JJ Howbert, GA Poore, BJ Reider, WN Shaw, GC Todd, and
JF Worzalla. Proc. Am. Assoc. Cancer Res. 27: 277,
1986.
PATENTS ISSUED (U.S.)
- US 8,524,702. Substituted benzoazepines as
toll-like receptor modulators. Howbert JJ, Dietsch G,
Hershberg R, Burgess LE, Doherty GA, Eary CT, Groneberg
RD, Jones Z.
- US 8,314,090. Methods of synthesis of
benzazepine derivatives. Howbert JJ, Kusukuntla VR,
Tretyakov A, Nielsen N, Krasik P, Jiang J-L, Yang HW.
- US 8,242,106. Toll-like receptor agonist
formulations and their use. Howbert JJ, Duvvuri M,
Hershberg R, Dietsch G.
- US 7,829,737. Protein tyrosine phosphatase
inhibitors and methods of use thereof. Blaskovich
MAT, Baughman T, Little T, Qabar M, Schultz LM, Hong F,
Patt W, Nagula G, Gage JL, Howbert JJ.
- US 7,504,389. Protein tyrosine phosphatase
inhibitors and methods of use thereof. Blaskovich
MAT, Baughman T, Little T, Patt W, Qabar M, Schultz LM,
Nagula G, Gage JL, Howbert JJ.
- US 7,176,310. Pyrimidinecarboxamide derivatives
and their use as anti-inflammatory agents.
Baughman TA, Boyce JP, Darwish I, Howbert JJ, Ihle NC,
Jackson RW, Jeffrey SC, Maeda D, Yager KM.
- US 6,906,046. Pharmaceutical uses and synthesis
of benzobicyclooctanes. Jackson RW, Darwish I,
Baughman TA, Howbert JJ.
- US 6,815,214. Pharmaceutical uses and synthesis
of diketopiperazines. Boyce JP, Howbert JJ, Tabone
JC.
- US 7,642,344. Methods and compositions for
determining the sequence of nucleic acid
molecules. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 7,247,434. Methods and compositions for
determining the sequence of nucleic acid
molecules. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 7,052,846. Methods and compositions for
analyzing nucleic acid molecules utilizing sizing
techniques. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 6,815,212. Methods and compositions for
enhancing sensitivity in the analysis of
biological-based assays. Van Ness J, Tabone JC, Howbert
JJ, Mulligan JT.
- US 6,623,928. Methods and compositions for
determining the sequence of nucleic acid
molecules. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 6,613,508. Methods and compositions for
analyzing nucleic acid molecules utilizing sizing
techniques. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 6,444,422. Computer method and system for
correlating data. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 6,312,893. Methods and compositions for
determining the sequence of nucleic acid
molecules. Van Ness J, Tabone JC, Howbert JJ,
Mulligan JT.
- US 6,027,890. Methods and compositions for
enhancing sensitivity in the analysis of
biological-based assays. Van Ness J, Tabone JC, Howbert
JJ, Mulligan JT.
- US 5,545,641. Methods of inhibiting
physiological conditions associated with an excess of
bradykinin. Bruns RF, Gehlert DR, Howbert JJ, Lunn
WHW.
- US 5,514,675. Naphthyl bradykinin receptor
antagonists. Bruns RF, Gehlert DR, Howbert JJ,
Lunn WHW.
- US 6,255,494. Benzimidazolyl neuropeptide Y
receptor antagonists. Britton TC, Bruns RF,
Cantrell BE, Hipskind PA, Lobb KL, Nixon JA, Ornstein
PL, Smith ECR, Zarrinmayeh H, Zimmerman DM, Nunes AM,
Howbert JJ.
- US 5,663,192. Heterocyclic neuropeptide Y
receptor antagonists. Bruns RF, Gehlert DR,
Howbert JJ, Lunn WHW.
- US 5,567,715. Methods of treating depression by
inhibiting physiological conditions associated with an
excess of neuropeptide Y. Bruns RF, Gehlert DR,
Howbert JJ, Lunn WHW.
- US 5,567,714. Methods of treating obesity by
inhibiting physiological conditions associated with an
excess of neuropeptide Y. Bruns RF, Gehlert DR,
Howbert JJ, Lunn WHW.
- US 5,576,337. Methods of treating anxiety by
inhibiting physiological conditions associated with an
excess of neuropeptide Y. Bruns RF, Gehlert DR,
Howbert JJ, Lunn WHW.
- US 5,562,862. Methods of inhibiting
physiological conditions associated with an excess of
neuropeptide Y. Bruns RF, Gehlert DR, Howbert JJ,
Lunn WHW.
- US 5,504,094. Use of benzothiophenes to treat
pain due to an excess of neuropeptide Y. Bruns RF,
Gehlert DR, Howbert JJ, Lunn WHW.
- US 5,491,140. Naphthyl tachykinin receptor
antagonists to treat physiological conditions.
Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
- US 6,869,957. Non-peptide tachykinin receptor
antagonists [diaminopropanes]. Cho SY, Crowell TA,
Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr.,
Lobb KL, Muehl BS, Nixon JA.
- US 6,727,255. Piperidinyl and piperazinyl
tachykinin receptor antagonists. Cho SY, Crowell
TA, Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH
Jr., Lobb KL, Muehl BS, Nixon JA.
- US 6,403,577. Hexamethyleneiminyl tachykinin
receptor antagonists. Cho SY, Crowell TA, Gitter
BD, Hipskind PA, Howbert JJ, Krushinski JH Jr., Lobb KL,
Muehl BS, Nixon JA.
- US 6,175,013. Imidazolinyl tachykinin receptor
antagonists [imidazolines]. Hipskind PA, Howbert
JJ, Muehl BS.
- US 5,684,033. Non-peptide tachykinin receptor
antagonists [diaminopropanes]. Cho SY, Crowell TA,
Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr.,
Lobb KL, Muehl BS, Nixon JA.
- US 5,670,499. Non-peptide tachykinin receptor
antagonists [diaminopropanes]. Cho SY, Crowell TA,
Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr.,
Lobb KL, Muehl BS, Nixon JA.
- US 5,565,568. 2-Acylaminopropanamides as
tachykinin receptor antagonists. Cho SYS, Hipskind
PA, Howbert JJ, Muehl BS, Nixon JA.
- US 5,643,926. Pyrazolidinone CCK and gastrin
antagonists and pharmaceutical formulations
thereof. Brown RF, Howbert JJ, Lobb KL, Neel DA,
Reel JK, Greenwood B.
- US 5,399,565. Pyrazolidinone CCK and gastrin
antagonists and pharmaceutical formulations
thereof. Greenwood B, Helton DR, Howbert JJ, Mitan
SJ, Rasmussen K.
- US 5,300,514. Pyrazolidinone CCK and gastrin
antagonists and pharmaceutical formulations
thereof. Brown RF, Howbert JJ, Lobb KL, Neel DA,
Reel JK, Greenwood B.
- US 5,565,494. Antitumor compositions and methods
of treatment [aminophenylsulfonylureas]. Grindey
GB, Grossman CS, Howbert JJ, Lobb KL, Ray JE, Toth JE.
- US 5,354,778. Antitumor compositions and methods
of treatment [trisubstituted
phenylsulfonyl-ureas]. Ray JE, Toth JE, Howbert
JJ.
- US 5,234,955. Antitumor compositions and methods
of treatment [trisubstituted
phenylsulfonyl-ureas]. Ray JE, Toth JE, Howbert
JJ.
- US 5,302,724. Antitumor compositions and methods
of treatment [thienylsulfonylureas]. Howbert JJ,
Mohamadi F, Spees MM.
- US 6,147,115. Antitumor compositions and methods
of treatment [alkylsulfonylureas]. Crowell TA,
Howbert JJ, Ward JS.
- US 5,216,026. Antitumor compositions and methods
of treatment [alkylsulfonylureas]. Crowell TA,
Howbert JJ, Ward JS.
- US 5,116,874. New N-(4-substituted
phenylaminocarbonyl)-heterocyclylsulfonamide cmpds. -
useful as anti-neoplastic agents. Harper RW,
Howbert JJ, Poore GA, Rieder BJ, Tao EVP.
- US 5,594,028. Anti-tumor methods and compounds
[cyclylphenylsulfonylureas]. Harper RW, Howbert
JJ, Poore GA, Rieder BJ, Tao EVP, Aikins JA.
|